



### ↑AFFIX CUSTOMER NO. LABEL ABOVE ↑

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE UTILITY APPLICATION AND FEE TRANSMITTAL, §(1.53(b))



Commissioner for Patents **BOX: PATENT APPLICATION** Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

- Juan J. PEREZ-VILLAR
   11 Carrousel Lane
   Mercerville, NJ 08619 USA
- (2) Han CHANG
  2 Ann's Court
  Princeton Junction, NJ 08550 USA
- (3) Wen-Pin YANG 245 Rutgers Lane Princeton, NJ 08540 USA
- (4) Yuli WU 3 Susanna Way Newtown, PA 18940 USA
- (5) Gena S. WHITNEY
  72 Hopatcong Drive
  Lawrenceville, NJ 08648 USA
- (6) Steven B. KANNER
  16 Honey Brook Drive
  Princeton, NJ 08540 USA
- Additional inventors are listed on a separate sheet

653136 v1

For: Identification and Cloning of a Full-length Human Clnk-related Gene, MIST (Mast Cell Immunoreceptor Signal Transducer)

Docket No.: D0029np

Enclo	Enclosed Are:						
129 118 1 10	total pages of Application, including:  page(s) of Specification  page(s) of Abstract  page(s) of Claims						
<u>21</u>	sheets of  Formal  Informal drawings page(s) of Declaration and Power of Attorney						
	<ul> <li>☐ Unsigned</li> <li>☐ Newly Executed</li> <li>☐ Copy from prior application</li> <li>☐ Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)</li> </ul>						
	REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35)  As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).						
	Incorporation by Reference:						
	The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.						
	Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b)						
	Signed statement attached deleting inventor(s) named in the prior application serial no, filed						
	Microfiche Computer Program (Appendix)						
$\boxtimes$	20 Page(s) of Sequence Listing Computer readable disk containing Sequence Listing Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same						
	Assignment Papers (assignment cover sheet and assignment documents)						
	☐ A check in the amount of \$40.00 for recording the Assignment ☐ Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order No						
	Assignment Papers filed in the parent application Serial No.						
	Certification of chain of title pursuant to 37 C.F.R. §3.73(b)						

	Priority is claimed under 35 U.S.C. §119 for: Application No(s), in (country).
	Certified Copy of Priority Document(s) []  filed herewith
	☐ filed in application Serial No, filed  ☐ English translation document(s) []  ☐ filed herewith  ☐ filed in application Serial No, filed
$\boxtimes$	Priority is claimed under 35 U.S.C. §119(e) for: Provisional Application No. <u>60/237,030</u> , filed <u>September 29, 2000</u> .
	Information Disclosure Statement
	Copy of [] cited references PTO Form-1449
	References cited in parent application Serial No, filed
	Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)
	A copy of related pending U.S. Application(s) Serial No(s):, filed, respectively, is attached hereto.
	A copy of related pending U.S. Application(s) entitled,, filed to inventor(s), respectively, is attached hereto.
	A copy of each related application(s) was submitted in parent application serial no, filed
	Preliminary Amendment
$\boxtimes$	Return receipt postcard (MPEP 503)
	This is a continuation divisional continuation-in-part of prior application serial no, filed, to which priority under 35 U.S.C. §120 is claimed.
	Cancel in this application original claims of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).
	The status of the parent application is as follows:
	A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until
	A copy of the Petition for Extension of Time in the co-pending parent application is attached.

	No Petition for Extension of Time and Fee therefor are necessary in the copending parent application.								
	Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.								
	Transfer the drawing(s) from the parent application to this application								
	Amend the specification by inserting before the first line the sentence:  This is a continuation divisional continuation-in-part of co-pending application Serial No, filed								
I. CA	ALCULATION (	OF APPLICATION FE	E						
		Number Filed	Number Extra	Rate	Basic Fee \$710.00/355.00				
Total Claims		40- 20 =	20x	\$18.00/ \$9.00	\$ 360.00				
Indep	pendent Claims	6- 3=	3x	\$80.00/ \$40.00	\$ 240.00				
Multiple Dependent Claims			If marked, add fee of \$270.00 (\$135.00)		\$ 270.00				
<u></u>	TOTAL: \$ <u>1580.00</u>								
	Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$								
$\boxtimes$	A check in the amount of \$1580.00 in payment of the application filing fees is attached.								
	Charge fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.								
$\boxtimes$	The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency with the								

parent application, or credit any overpayment to Deposit Account No. <u>13-4500</u>, Order No. <u>3053-4113US1</u>. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

	No Petition for Extension of Time and Fee therefor are necessary in the copending parent application.							
	Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.							
	Transfer the drawing(s) from the parent application to this application							
	Amend the specification by inserting before the first line the sentence:  This is a continuation divisional continuation-in-part of co-pending application Serial No, filed							
I. CA	LCULATION (	OF APPLICATION FEI	E					
		Number Filed	Number Extra	Rate	Basic Fee \$710.00/355.00			
Total Claims		40- 20 =	20x	\$18.00/ \$9.00	\$ 360.00			
Indep	endent Claims	6- 3 =	3x	\$80.00/ \$40.00	\$ 240.00			
Multiple Dependent Claims			If marked, add fee of \$270.00 (\$135.00) \$ 270.00		\$ 270.00			
					\$ <u>1580.00</u>			
Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$								
$\boxtimes$	A check in the amount of \$1580.00 in payment of the application filing fees is attached.							
	Charge fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.							
$\boxtimes$	The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4113US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.							

Docket No.: D0029np

Docket No.: D0029np

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: September 28, 2001

By: Leslie A. Serunian

Leslie A. Serunian Registration No. <u>35,353</u>

### Correspondence Address:

Bristol-Myers Squibb Company Route 206 and Provinceline Road Mail Stop D33-05 Princeton, New Jersey 08540 (609) 252-3953 Telephone (609) 252-4256 Facsimile

### Sender's Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053

(212) 758-4800 Telephone (212) 751-6849 Facsimile

BMS Docket No. D0029np

## M&F, LLP Ref. No: 3053-4113US1

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Juan J. PEREZ-VILLAR et al.

Group Art Unit:

To Be Assigned

Serial No.:

To Be Assigned

Examiner:

To Be Assigned

Filed:

September 28, 2001 (Herewith)

For:

Identification and Cloning of a Full-length Human Clnk-related Gene, MIST (Mast Cell

Immunoreceptor Signal Transducer)

### **EXPRESS MAIL CERTIFICATE**

Express Mail Label No.:

EL 912 003 539 <u>US</u>

Date of Deposit:

September 28, 2001

I hereby certify that the following attached paper(s) and/or fee(s)

Utility Application and Fee Transmittal (5 pages); 1.

Utility Application containing 129 total pages, including 118 pages of Specification, 10 pages of Claims, 1 page of Abstract;

21 sheets of Drawings (Figs.1A/1B-15A/15B); 3.

20 pages of Sequence Listing; 4.

3.5 inch disk containing Sequence Listing in Computer-readable form 5.

Statement of Identity pursuant to 37 CRF 1.821(f); 6.

Filing Fee (check for \$1580.00) 7.

8. Return Postcard

is/are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: BOX: PATENT APPLICATION., the Commissioner for Patents, Washington, D.C. 20231.

fee)

Jesus R. Remedios

(Typed or printed name of person mailing papers(s) and/or

(Signature of person mailing paper(s) and/or fee)

Sender's Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone Facsimile (212) 751-6849

The first than AND THE PARTY OF T

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Juan J. PEREZ-VILLAR et al.

Serial No.

To Be Assigned

Group Unit: To Be Assigned

Filed

Herewith (September 28, 2001) Examiner: To Be Assigned

For

Identification and Cloning of a Full-length Human Clnk-

related Gene, MIST (Mast Cell Immunoreceptor Signal

Transducer)

Commissioner for Patents Washington, D.C. 20231

### Statement Under 37 C.F.R. §1.821(f) or §1.825(b)

Dear Sir:

I hereby certify that:

- [X] The paper Sequence Listing submitted herewith and computer readable Sequence Listing attached hereto are identical (37 C.F.R. §1.821(f)).
- [ ] The substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are identical. No new matter is included (37 C.F.R. §1.825(b)).

Respectfully submitted,

MORGAN & FINNEGAN, LLP

Date: September 28, 2001

Leslie A. Serunian Reg. No. 35,353

**CORRESPONDENCE ADDRESS:** 

Bristol-Myers Squibb Company Route 206 and Provinceline Road Princeton, New Jersey 08543-4000

Telephone: (609) 252-3953 Facsimile: (609) 252-4526 SENDER'S ADDRESS:

Morgan & Finnegan, LLP

345 Park Avenue

New York, New York 10154-0053

Telephone: (212) 758-4800 Facsimile: (212) 751-6849

652824 v1